OpenEvidence raises $150M, valued at $5B, as open-source platform expands globally
Current overview (not historical)
OpenEvidence secured $150 million in Series C funding, achieving a $5 billion valuation and open-sourcing its platform to expand into 100 low- and middle-income countries. While a Mayo Clinic study demonstrated accurate evidence recommendations, the platform's clinical efficacy remains disputed; it underperformed in benchmark tests, and NYU Langone neurosurgeon Eric Oermann criticized the lack of performance studies and clinical implementation guidelines for individual AI tools.
Written with AI from the reporting · updated 10/21/2026
Expand the detailed fact route and sources
Story route
A station-by-station route from the first public evidence onward; every station carries its own evidence and uncertainty.
- 1Unclassified fact stationOct 21, 00:00recorded Oct 21, 23:57single sourcerevised
OpenEvidence获评临床效果有限
Read original source ↗ Ars Technica · AIReplay this moment in the explorerEvidence & revisions · 1 source records
- Subject：
- OpenEvidence
- Action：
- 评估临床效果
- Object：
- AI工具在患者案例研究中的表现
- Occurred (fact side)：
- Oct 21, 00:00
- Published (valid side)：
- Oct 21, 23:14
- First seen (known side)：
- Oct 21, 23:57
Fact stationSingle source · one-sided claimRevisedCopy may have been revised later; time replay is bounded. Layer labels group reading only, not causation between layers.
Uncertainty marks flag where to check the sources; they are not proven causation.
Report timeline
Explore every side through dated source reports.
- Ars Technica · AIRelated fact: single sourceSource report revisedAd-powered AI startup OpenEvidence expands global reach and faces mixed clinical validation
Report first recorded Oct 21, 23:57
OpenEvidence, a $15 billion ad-powered AI startup, has expanded its reach to 100 low- and middle-income countries, supported by Anthropic's Claude Science platform for literature mining. While a Mayo Clinic study found it provided accurate, evidence-based recommendations in sampled patient cases, other research, including a June paper in Nature, showed it underperformed general-purpose AI models like Google’s Gemini and OpenAI’s GPT on clinical benchmarks. Eric Oermann, a neurosurgeon at NYU Langone, noted a lack of research on individual AI tool performance and guidance for clinical implementation.
Read original source ↗
Event discussion
Reader opinions are hosted on GitHub Discussions; posting requires a GitHub account. Comments are not verified facts.